Insider Trade: Steven Pacelli Sold 10,300 Shares of DexCom, Inc. (NASDAQ:DXCM)

November 29, 2016 - By Hazel Jackson

 Insider Trade: Steven Pacelli Sold 10,300 Shares of DexCom, Inc. (NASDAQ:DXCM)

Steven Pacelli Insider Sell

An insider of the company Dexcom Inc, Steven Pacelli also its EVP – Strategy & Corp. Dev., disclosed his trading activities with the Security and Exchange Commission on November 28, 2016. As discovered in the document, Steven had sold 10,300 shares of the Pinksheet-listed company. The total insider trade was worth $724,260 USD. At the time of the trade the price of a share was $70.3. Now, Steven Pacelli owns 110,409 shares which make up about 0.13% of the Company’s total market cap.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Out of 12 analysts covering Dexcom (NASDAQ:DXCM), 11 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 92% are positive. $120 is the highest target while $70 is the lowest. The $90.88 average target is 27.77% above today’s ($71.13) stock price. Dexcom has been the topic of 18 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Buy” rating given on Wednesday, February 24 by Jefferies. On Monday, October 31 the stock rating was upgraded by BTIG Research to “Buy”. The firm has “Buy” rating given on Friday, July 15 by Deutsche Bank. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Overweight” rating given on Wednesday, February 24 by JP Morgan. As per Monday, February 8, the company rating was downgraded by Robert W. Baird. The stock has “Buy” rating given by Piper Jaffray on Friday, August 7. The rating was upgraded by Sterne Agee CRT on Thursday, October 15 to “Buy”. As per Wednesday, November 2, the company rating was maintained by Canaccord Genuity. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Overweight” rating by Morgan Stanley on Monday, November 2. The firm earned “Overweight” rating on Thursday, September 17 by JP Morgan.

Insitutional Activity: The institutional sentiment decreased to 1.1 in 2016 Q2. Its down 0.25, from 1.35 in 2016Q1. The ratio fall, as 30 funds sold all DexCom, Inc. shares owned while 77 reduced positions. 46 funds bought stakes while 98 increased positions. They now own 82.43 million shares or 5.55% more from 78.09 million shares in 2016Q1.

State Street Corporation, a Massachusetts-based fund reported 1.00M shares. Panagora Asset Management Inc holds 0% or 1,355 shares in its portfolio. Wells Fargo And Mn holds 0.07% of its portfolio in DexCom, Inc. (NASDAQ:DXCM) for 2.23M shares. The New York-based Bridger Management Ltd Com has invested 3.63% in DexCom, Inc. (NASDAQ:DXCM). Ftb Inc accumulated 0.04% or 3,780 shares. Vigilant Cap Mngmt Lc accumulated 0% or 161 shares. Bnp Paribas Inv Prns has 112,578 shares for 0.08% of their US portfolio. The Pennsylvania-based Vantage Advsr Lc has invested 0% in DexCom, Inc. (NASDAQ:DXCM). Advsrs Asset Mngmt Inc owns 3,079 shares or 0% of their US portfolio. Brown Advisory has invested 0% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Moreover, Great West Life Assurance Can has 0.02% invested in DexCom, Inc. (NASDAQ:DXCM) for 93,170 shares. The California-based Blackrock Fund Advsr has invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). The New York-based Amer Int Group has invested 0% in DexCom, Inc. (NASDAQ:DXCM). Cibc Ww has invested 0.01% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). The New Jersey-based Prudential Fincl has invested 0.01% in DexCom, Inc. (NASDAQ:DXCM).

Insider Transactions: Since June 7, 2016, the stock had 0 insider buys, and 61 insider sales for $55.78 million net activity. The insider LORD JONATHAN T MD sold $906,399. Shares for $1.08M were sold by MOY JEFFREY on Tuesday, July 19. Balo Andrew K sold $451,300 worth of DexCom, Inc. (NASDAQ:DXCM) on Wednesday, August 10. The insider Pacelli Steven Robert sold $899,473. $170,325 worth of DexCom, Inc. (NASDAQ:DXCM) shares were sold by FOLETTA MARK G. $2.91M worth of shares were sold by VALDES JORGE A on Tuesday, August 9. $333,392 worth of shares were sold by LISTER JOHN on Friday, September 9.

About 1.01M shares traded hands. DexCom, Inc. (NASDAQ:DXCM) has risen 5.34% since April 25, 2016 and is uptrending. It has underperformed by 0.68% the S&P500.

Dexcom, Inc. is a medical device company. The company has a market cap of $6.03 billion. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. It currently has negative earnings. The Company’s products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

According to Zacks Investment Research, “Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.”

Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on February, 28. They expect $-0.07 EPS, down 450.00% or $0.09 from last year’s $0.02 per share. After $-0.22 actual EPS reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -68.18% EPS growth.

More important recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Fool.com which released: “Here’s Why DexCom, Inc. Is Plunging Today” on November 02, 2016, also Prnewswire.com published article titled: “With Health Canada approval, Dexcom G5® Mobile CGM System is the First and ..”, Prnewswire.com published: “Dexcom and Major League Soccer AT&T Rookie of the Year Jordan Morris Kick-off ..” on November 10, 2016. More interesting news about DexCom, Inc. (NASDAQ:DXCM) was released by: Globenewswire.com and their article: “DexCom, Inc. (Nasdaq: DXCM) to Ring The Nasdaq Stock Market Opening Bell” with publication date: November 11, 2016.

DXCM Company Profile

Dexcom, Inc. (Dexcom), incorporated on May 13, 1999, is a medical device company. The Firm is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. The Company’s products consist of SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. The Firm had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system in the European Union, Australia, New Zealand and the countries in Asia and Latin America.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>